156 related articles for article (PubMed ID: 38155795)
1. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk of HF and AF.
Ohno R; Kaneko H; Suzuki Y; Okada A; Matsuoka S; Ueno K; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Node K; Yasunaga H; Komuro I
JACC Asia; 2023 Dec; 3(6):908-921. PubMed ID: 38155795
[TBL] [Abstract][Full Text] [Related]
2. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study.
Wei Z; Huang Z; Song Z; Zhao W; Zhao D; Tan Y; Chen S; Yang P; Li Y; Wu S
Diabetol Metab Syndr; 2023 Jun; 15(1):137. PubMed ID: 37355613
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
5. Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease.
Perdomo CM; Núñez-Córdoba JM; Ezponda A; Mendoza FJ; Ampuero J; Bastarrika G; Frühbeck G; Escalada J
Front Med (Lausanne); 2022; 9():1023583. PubMed ID: 36341262
[TBL] [Abstract][Full Text] [Related]
6. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
7. Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study.
Wu S; Li Y; Zhang Y; Su X; Zuo Y; Chen G; Xu G; Chen S; He Y; Wang A
Circ Heart Fail; 2024 Feb; 17(2):e010841. PubMed ID: 38348678
[TBL] [Abstract][Full Text] [Related]
8. Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study.
Zhang Y; Xia Z; Cai X; Su X; Jin A; Mei L; Jing J; Wang S; Meng X; Li S; Wang M; Wei T; Wang Y; He Y; Pan Y
Cardiovasc Diabetol; 2023 Dec; 22(1):342. PubMed ID: 38093371
[TBL] [Abstract][Full Text] [Related]
9. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
Hashimoto Y; Hamaguchi M; Okamura T; Nakanishi N; Obora A; Kojima T; Fukui M
J Diabetes Investig; 2022 Feb; 13(2):308-316. PubMed ID: 34561962
[TBL] [Abstract][Full Text] [Related]
10. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.
Decoin R; Butruille L; Defrancq T; Robert J; Destrait N; Coisne A; Aghezzaf S; Woitrain E; Gouda Z; Schino S; Klein C; Maboudou P; Brigadeau F; Klug D; Vincentelli A; Dombrowicz D; Staels B; Montaigne D; Ninni S
Front Endocrinol (Lausanne); 2022; 13():957245. PubMed ID: 36120456
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
12. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Lee H; Lim TS; Kim SU; Kim HC
Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
[TBL] [Abstract][Full Text] [Related]
13. Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study.
Lee SM; Cho GJ; Wi WY; Norwitz ER; Koo BK; Lee J; Jung YM; Kwak SH; Park CW; Jun JK; Joo SK; Oh MJ; Kim W; Park JS
Hepatol Int; 2023 Apr; 17(2):367-376. PubMed ID: 36542262
[TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation.
Zhou BG; Ju SY; Mei YZ; Jiang X; Wang M; Zheng AJ; Ding YB
Front Endocrinol (Lausanne); 2023; 14():1160532. PubMed ID: 37476492
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
Lee H; Lee HW; Kim SU; Chang Kim H
Clin Transl Gastroenterol; 2022 Jan; 13(1):e00435. PubMed ID: 35080508
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
18. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
[TBL] [Abstract][Full Text] [Related]
19. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
[TBL] [Abstract][Full Text] [Related]
20. MAFLD and NAFLD in the prediction of incident chronic kidney disease.
Kwon SY; Park J; Park SH; Lee YB; Kim G; Hur KY; Koh J; Jee JH; Kim JH; Kang M; Jin SM
Sci Rep; 2023 Jan; 13(1):1796. PubMed ID: 36720976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
